The top 15 R&D budgets

In the world of drug development, you're only as good as your pipeline. As many companies' older blockbuster drugs go off-patent, analysts are looking at pipelines to see who'll have what it takes to survive and grow, and which companies will fall behind in the race to develop new drugs.

A recent EU report ranked the world's largest R&D budgets, and Pfizer took the lead--not just among drug developers but among all industries--with a staggering $8.34 billion budget in 2006. But as this report shows, spending more money doesn't necessarily make for a better pipeline. Take a look at this list of the top 15 pharmaceutical R&D budgets to find out how they're spending all those billions of dollars.

- see this special report for more

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.